US SEC Trading Suspension Halt Orders — October 22, 2026

Approximately $350.0 million gross private placement closed October 14, 2026, against pre-transaction stockholders' equity of $2,153,000 (FY2025 10-K), implying a large equity cure if classification holds

Company believes it has regained compliance with the $2.5 million equity requirement; Nasdaq Panel hearing on November 10, 2026 may be cancelled upon Staff confirmation

Filed the delinquent 2025 Form 10-K on October 16, 2026, reducing the reporting gap, but Q1 and Q2 2026 10-Qs remain outstanding

Delisting determination issued October 16, 2026 after the October 12, 2026 extension expired; Hearings Panel request due October 23, 2026, with suspension risk after 15-day stay

Closed below the $1.00 minimum bid price for 30 consecutive business days; 180-day cure window to April 19, 2027, with possible second 180-day period if eligible

Series B and most Series C preferred expected to sit outside permanent stockholders' equity pending approvals, so the equity cure remains contingent on stockholder action and authorized share increase

Company will seek an extended stay pending hearing, but no assurance the Panel grants it; hearing typically 30-45 days after request

Failure to file 2025 10-K and Q1/Q2 2026 10-Qs by October 12, 2026 led to a Staff delisting determination; suspension occurs at end of 15-day stay absent an extended stay or post-hearing reinstatement

Hearings Panel request must be submitted by October 23, 2026, one day after the filing date, leaving minimal margin for error

Equity compliance depends on FY2026 10-K evidence; Q3 2026 10-Q will not reflect the merger or financing, creating a reporting-timing gap

Series B and most Series C preferred classified outside permanent equity pending stockholder approval; failure to obtain approvals could reverse the equity cure

Waiver terminates on the later of Series C conversion approval and authorized share increase effectiveness, creating a conditional dependency

Sub-$1.00 closing price for 30 consecutive business days; if cure is not achieved by April 19, 2027 (or second period), Nasdaq would issue a delisting notice

Any delisting determination could be appealed, but the company cannot assure success

Three of three filings in the stream involve Nasdaq Rule 5000-series or 5550 enforcement, indicating elevated exchange-level scrutiny of compliance deficiencies among small caps

$350.0 million placement against $2.153 million pre-deal equity could drive a substantial stockholders' equity increase, and a November 10, 2026 hearing cancellation would remove delisting overhang

Series C conversion approval and authorized share increase are the gating events; successful votes would finalize classification into permanent equity and end the cash settlement waiver

Hearings Panel can reinstate trading in a post-hearing written decision; a favorable outcome after the 30-45 day hearing window would restore listing status

Company is actively working on Q1 and Q2 2026 10-Qs; filing both would address the core deficiency underlying the delisting determination

Sub-$1.00 price for 30 days creates a reversal opportunity if shares close at or above $1.00 for 10 consecutive business days before April 19, 2027

Meeting market value of publicly held shares and initial listing standards (excluding bid price) and providing written notice could extend the cure window by 180 days

Alaunos (November 10 hearing), AAME (October 23 request, 30-45 day hearing), and SNES (April 19, 2027 deadline) offer distinct, dated catalysts for event-driven strategies

All three filings reflect exchange enforcement on distinct rule categories (delinquent filings, stockholders' equity, minimum bid price), indicating broad listing-standard scrutiny rather than an isolated event [pattern across 3/3 filings]

Alaunos demonstrates a template in which large private placements and reverse-merger structures are used to rapidly restore stockholders' equity, with compliance contingent on preferred-stock classification and shareholder approvals [implication: dilution and governance risk accompany cure]

AAME shows that failure to file periodic reports, even after extensions, can trigger delisting independent of financial performance, making filing calendars a key monitoring metric [implication: operational/governance failures are often more acute than financial ones]

Nasdaq's 180-day bid price periods, 15-day automatic stays, and hearing windows create a structured, date-driven catalyst path across the stream, favoring event-calendar monitoring [implication: timing-based strategies are relevant]

None of the three filings contains revenue, margin, insider, or capital-allocation data; enriched fields are empty, so investment conclusions rely on compliance status rather than financial trend analysis [implication: fundamental underwriting requires supplemental filings]

Filing of request and extended-stay motion due by October 23, 2026; monitor for suspension notice after 15-day automatic stay

Filing status is critical to demonstrating compliance before the 30-45 day hearing window; watch for EDGAR submissions

Scheduled November 10, 2026; cancellation depends on Nasdaq Staff confirmation of equity compliance

Series C conversion approval and authorized share increase effectiveness will determine preferred classification and cash settlement waiver termination; date to be confirmed

Evidence of equity compliance must be filed with the 10-K; monitor for timing and any Staff follow-up

Track daily closes against $1.00 threshold; cure requires 10 consecutive business days at or above $1.00 before April 19, 2027

Confirm whether the company submits notice to qualify for a second 180-day period, and whether it meets publicly held share value standards

Watch for additional delinquent-filer delisting determinations across small caps as an indicator of broader sector stress